|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.49 EUR | -0.11% |
|
+4.05% | -26.06% |
| 07-01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
| 07-01 | New semester, new state of mind |  |
Jan 19 (Reuters) - French biotech firm Valneva said on Wednesday that preliminary studies showed that three doses of its inactivated COVID-19 vaccine candidate neutralised the Omicron variant of the disease. (Reporting by Sarah Morland; Editing by Hugh Lawson)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.06% | 529M | |
| +25.83% | 47.96B | |
| +44.70% | 41.47B | |
| +0.69% | 42.45B | |
| +30.52% | 31.6B | |
| +22.30% | 28.63B | |
| -6.35% | 28.03B | |
| +49.25% | 14.56B | |
| +49.18% | 14.14B | |
| +3.45% | 12.58B |
VALNEVA 
